Chemical Nametbo-filgrastim
Dosage FormInjection (subcutaneous; 300 mcg/ 0.5 mL, 480 mcg/ 0.8 mL)
Drug ClassMiscellaneous
CompanyTeva Pharmaceuticals USA, Inc.
Approval Year2012


  • Indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Neutroval (tbo-filgrastim) Prescribing Information2012Teva Pharmaceuticals USA, North Wales, PA